Replies to post #203610 on Elite Pharmaceuticals Inc (ELTP)

[rollin2nyte]

Because the CAGR is in the APAC:

http://www.prnewswire.com/news-releases/global-opioids-market-is-anticipate-to-garner-us4216-bn-revenue-by-2021-persistence-market-research-567328041.html

North America and Europe have been estimated to collectively account for over 85% revenue share of the total opioids market in 2015. Asia-Pacific is projected to be the fastest-growing market, owing to increasing awareness for cancer pain management, a presence of large patient pool suffering from terminal conditions and reformed regulatory guidelines for the prescription of opioids.

It's much easier to enter a market with little to no competition.

[no2koolaid]

It was not a focus but an awareness of the potential a global pharma can offer...Big companies do not dismiss 20% of a market if they have the capabilities and BP firms do. And, by the way, the 20% outside the US often cited is not only a low estimate according to some analysts, it fails to recognize the increasing middle class buying power in emerging countries, not to mention increasing access to healthcare that drives the desire for and access to new meds by what is also an increasingly aging population.

[rollin2nyte]

Also:

http://www.jonesday.com/how-to-protect-pharmaceutical-products-in-china-with-or-without-a-patent-04-19-2006/

Monitoring Period Exclusivity. After a new drug is approved for entering the market in China, the State Food and Drug Administration (“SFDA”) will impose a “monitoring period” to observe the safety and efficacy of the drug. During the monitoring period, the SFDA will not grant approval to any other enterprises to manufacture, distribute, or import this drug, unless the competing product has been approved for entering clinical trials in China prior to the beginning of the monitoring period. The monitoring period exclusivity is available for new drugs manufactured in China.

The monitoring period lasts from three to five years, starting on the issuance date of the drug manufacturing certificate.